0001140361-22-020826.txt : 20220526 0001140361-22-020826.hdr.sgml : 20220526 20220526171527 ACCESSION NUMBER: 0001140361-22-020826 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220526 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220526 DATE AS OF CHANGE: 20220526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 22971308 BUSINESS ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 8-K 1 brhc10038205_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2022

PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
001-37568
26-4231384
     
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
25B Vreeland Road, Suite 300, Florham Park, NJ 07932
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 ☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01
Other Events.
On May 26, 2022, PDS Biotechnology Corporation issued a press release announcing an upcoming poster discussion presentation of clinical data from the ongoing Phase 2 triple combination trial led by the National Cancer Institute (NCI), of the National Institutes of Health (NIH), at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022 in Chicago and online. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
  
Description
     
 
Press Release Dated May 26, 2022.
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL Document)

Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 PDS BIOTECHNOLOGY CORPORATION
     
Date: May 26, 2022
 By:
/s/ Frank Bedu-Addo, Ph.D.
 
Name:
Frank Bedu-Addo, Ph.D.
 
Title:
President and Chief Executive Officer


EX-99.1 2 brhc10038205_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022


 •
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months

•
75% of CPI naïve patients alive at median follow up of 17 months

•
Anti-tumor objective responses seen in 88% of CPI naïve patients and 63% CPI refractory patients (high dose of M9241)

•
Study shows early evidence of durable clinical responses

•
Company to host conference call and webcast on June 7, 2022 at 8:00 AM EDT

FLORHAM PARK, N.J., May 26, 2022 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced an upcoming poster discussion presentation of clinical data from the ongoing Phase 2 triple combination trial led by the National Cancer Institute (NCI), of the National Institutes of Health (NIH), at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022 in Chicago and online.

The Phase 2 triple combination trial (NCT04287868) is evaluating the safety and efficacy of PDS0101, an investigational HPV16-targeted immunotherapy, in combination with two investigational immune-modulating agents: M9241, a tumor-targeting IL-12 (immunocytokine), and bintrafusp alfa, a bifunctional checkpoint inhibitor (PD-L1/ TGF-β). The triple combination is being studied in CPI-naïve and -refractory patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar cancers who have failed prior therapy. PDS0101 is administered as two separate 0.5 ml subcutaneous injections every 4 weeks; bintrafusp alfa at 1,200 mg by IV infusion every 2 weeks; and M9241 at an initial high dose of 16.8 mcg/kg by subcutaneous injection every 4 weeks or at a low dose of 8 mcg/kg by subcutaneous injection every 2 weeks. Objective response is measured by radiographic tumor responses according to RECIST 1.1.  Early data from the study suggests that the triple combination is preferentially active in HPV16-positive cancer.

Immune checkpoint inhibitors (CPIs) have been evaluated in the treatment of advanced HPV-associated cancers including anal, cervical, head and neck, penile, vaginal and vulvar cancers. In these published studies, objective response rates have ranged from 13–24%*, and two CPIs are FDA approved to treat head and neck cancer and cervical cancer. Unfortunately, the majority of patients who receive CPI therapy continue to progress.  Historical median survival rates for CPI refractory patients, is 3-4 months**. Combinations of CPI and chemotherapy are being evaluated in refractory HPV-associated cancers. For most patients with CPI refractory HPV-associated disease, there is no clear effective standard of care therapy.
 
Data from 30 cancer patients (9 cervical, 2 vaginal/vulvar, 6 anal, 13 oropharyngeal) are included in the poster. Highlights are as follows:

 •
Objective response (OR = >30% tumor reduction) was seen in 88% (7/8) of patients with checkpoint-naive disease; 4/7 (57%) patients’ responses are ongoing (median 17 months).

•
With checkpoint refractory patients: M9241 dosing appears to affect response rates, with 5/8 (63%) patients receiving M9241 at 16.8 mcg/kg achieving an OR compared to 1/14 (7%) patients who received M9241 at 8 mcg/kg achieving an OR; 4/6 (67%) patients’ responses are ongoing (median 12 months).

•
Tumor reduction was seen in 45% (10/22) of patients with checkpoint-refractory disease, including patients receiving high or low dose M9241.

•
In checkpoint refractory patients treated with high or low dose M9241, survival outcomes were similar (p=0.96 by Kaplan Meier analysis). At a median of 12 months of follow up 17/22 (77%) of patients were alive.

•
In checkpoint naïve patients 6/8 (75%) were alive at median 17 months of follow up.

•
Similar OR and survival were seen across all types of HPV16-positive cancers.

•
Preliminary safety data: 13/30 (43%) of patients experienced Grade 3 treatment-related adverse events (AEs), and 2/30 patients (7%) experienced Grade 4 AEs. There were no grade 5 treatment-related AEs.

•
The study results to date strongly suggest, in agreement with the published preclinical studies, that all 3 drugs contribute to the clinical outcomes.

“We believe achieving a 77% survival at 12 months follow up in CPI refractory patients and 75% survival at 17 months follow up in CPI naïve patients, as well as significant tumor reduction in these refractory patients with advanced HPV16-positive cancers is promising. These data continue to support clinical investigation of our Versamune® platform’s potential to induce high levels of tumor-specific CD8+ killer T-cells to attack a broad range of cancers,” stated Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. “These results, combined with the previously reported data from this trial, strengthen our confidence that this novel combination has the potential to provide improved clinical outcomes and overall survival for patients with refractory HPV-associated cancers.”

“Based on these results, the combination of PDS0101, bintrafusp alfa, and M9241 appears to have a manageable safety profile along with early evidence of clinical activity in patients with CPI-naïve and -refractory advanced HPV16-positive cancer,” said, James Gulley, M.D., Ph.D., Acting NCI Clinical Director, Co-Director of the Center for Immuno-Oncology, Center for Cancer Research, NCI. “Observing patients with ongoing clinical responses to treatment after 17 and 12 months is encouraging, as patients with advanced, refractory HPV16-associated cancers typically have limited treatment options.”

The abstract is now available online on the ASCO conference website: https://am.asco.org/.

Abstract/Poster Number: 2518
Abstract Title: Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies.
Presenting Author: James Gulley, Ph.D., National Cancer Institute
Date: Sunday, June 5, 2022
Time: 8:00 AM-11:00 AM; 11:30 AM-1:00 PM CDT

PDS Biotech is presenting a second abstract #6041 from a non-NCI clinical study which presents clinical results for a PDS0101-KEYTRUDA® combination in HPV16-positive head and neck cancer. The press release describing these data can be seen on the company website here.

The company will be hosting a conference call on Tuesday, June 7 at 8:00 AM EDT to discuss the data presented at ASCO from the two clinical studies. A live webcast of the event will be available online in the investor relations section of the company's website at https://pdsbiotech.com/investors/news-center/events.

For patients interested in enrolling in the NCI-led clinical study, please call NCI’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email NCIMO_Referrals@mail.nih.gov, and/or visit the website: https://trials.cancer.gov.

*Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum and cetuximab-refractory
head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 2017;35:1542–9.
Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD- 1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036–41.
Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in
KEYNOTE-012. Br J Cancer 2018;119:153–9.
Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–67.
Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:446–53.
Chung HC, Ros W, Delord J-P, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37:1470–8.
**Strauss J, et al. J Immunother Cancer 2020;8:e001395. doi:10.1136/jitc-2020-001395

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. We believe our Versamune®-based products are demonstrating the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells including long-lasting memory T-cell responses. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company continues to advance its pipeline of candidates to address a wide range of cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® and Infectimune™-based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® and Infectimune™-based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.
Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital


 EX-101.SCH 3 pdsb-20220526.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pdsb-20220526_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 pdsb-20220526_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 26, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 26, 2022
Entity Registrant Name PDS BIOTECHNOLOGY CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-37568
Entity Tax Identification Number 26-4231384
Entity Address, Address Line One 25B Vreeland Road
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code 800
Local Phone Number 208-3343
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001472091
Title of 12(b) Security Common Stock, par value $0.00033 per share
Trading Symbol PDSB
Security Exchange Name NASDAQ
XML 7 brhc10038205_8k_htm.xml IDEA: XBRL DOCUMENT 0001472091 2022-05-26 2022-05-26 false 0001472091 NASDAQ 8-K 2022-05-26 PDS BIOTECHNOLOGY CORPORATION DE 001-37568 26-4231384 25B Vreeland Road Suite 300 Florham Park NJ 07932 800 208-3343 false false false false Common Stock, par value $0.00033 per share PDSB false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10038205_8k.htm brhc10038205_ex99-1.htm pdsb-20220526.xsd pdsb-20220526_lab.xml pdsb-20220526_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10038205_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10038205_8k.htm" ] }, "labelLink": { "local": [ "pdsb-20220526_lab.xml" ] }, "presentationLink": { "local": [ "pdsb-20220526_pre.xml" ] }, "schema": { "local": [ "pdsb-20220526.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pdsb", "nsuri": "http://pdsbiotech.com/20220526", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10038205_8k.htm", "contextRef": "c20220526to20220526", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10038205_8k.htm", "contextRef": "c20220526to20220526", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-22-020826-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-020826-xbrl.zip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end